Jaguar Health, Inc. JAGX shares are trading higher Tuesday after the company reported approval for all proposals at its special meeting of stockholders.
The Details: Jaguar Health reported all proposals were approved by stockholders, and the company will not be implementing a reverse split at this time.
“As we announced last week, the Company received formal notice that the Listing Qualifications Staff of The Nasdaq Stock Market LLC has granted Jaguar an additional grace period, through August 13, 2024, to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. Although we do not intend to effect a reverse split of the Company’s issued and outstanding voting common stock at the present time, seeking the discretion to implement actions, if necessary to maintain Jaguar’s Nasdaq listing, is an important responsibility of the Board, and we are grateful to our shareholders for voting to approve the related proposal,” said Lisa Conte, Jaguar’s CEO.
Related News: What’s Going On With Chinese EV Stocks Nio And XPeng?
Should I Sell My JAGX Stock? When deciding to hold on to or sell a stock, investors should consider their time horizon, unrealized gains and total return.
Shares of Jaguar Health have decreased by 84.75% in the past year. An investor who bought shares of Jaguar Health at the beginning of the year would take a loss of $0.06 per share if they sold it today. The stock has risen 26.05% over the past month, meaning an investor who bought shares on March 1 would see a capital loss of $0.05.
Investors might also consider market dynamics. The Relative Strength Index could be used to indicate whether a stock is overbought or oversold. Jaguar Health stock currently has an RSI of 62.84, indicating neutral conditions.
For access to advanced charting and analysis tools and stock data, check out Benzinga PRO. Try it for free.
JAGX Price Action: According to Benzinga Pro, Jaguar Health shares are up 11.11% at 10 cents after-hours Tuesday.
Photo: Gerd Altmann from Pixabay
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.